Live feed16:05:00·825dPRReleasevia QuantisnowTakeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology AssetByQuantisnow·Wall Street's wire, on your screen.PTGX· Protagonist Therapeutics Inc.TAK· Takeda Pharmaceutical Company LimitedHealth Care
